DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY-Reference-Cited by-同舟云学术

DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY

Published:2004-01-26 Issue:2 Volume:32 Page:172-177
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Ward Keith W.,Stelman Gary J.,Morgan Jayme A.,Zeigler Kelli S.,Azzarano Leonard M.,Kehler Jonathan R.,McSurdy-Freed Jeanelle E.,Proksch Joel W.,Smith Brian R.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference26 articles.

1. Pharmacokinetics of Ketoconazole Administered Intravenously to Dogs and Orally as Tablet and Solution to Humans and Dogs

2. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery

3. In vitro assessment of human cytochrome P450

4. Rapid Determination of Pharmacokinetic Properties of New Chemical Entities: In vivo Approaches

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approaches to minimize the effects of P‐glycoprotein in drug transport: A review;Drug Development Research;2022-02

2. Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention;Journal of Experimental Medicine;2021-03-02

3. P-glycoproteins play a role in ivermectin resistance in cyathostomins;International Journal for Parasitology: Drugs and Drug Resistance;2017-12

4. Regulation of hepatic abcb4 and cyp3a65 gene expression and multidrug/multixenobiotic resistance (MDR/MXR) functional activity in the model teleost, Danio rerio (zebrafish);Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology;2017-10

5. Fluticasone furoate and vilanterol trifenatate combination therapy for the treatment of asthma;Expert Review of Respiratory Medicine;2016-06-08